Biofeedback physical therapy improves CPPS symptoms
May 1st 2005Istanbul, Turkey--Biofeedback physical therapy and pelvic floor re-education appear to offer symptomatic improvement in men with chronic pelvic pain syndrome type III, Dutch researchers say. The techniques appear to work by improving relaxation and demonstrating proper use of pelvic floor muscles.
Rapidly rising PSA is good indicator of metastasis
May 1st 2005Orlando, FL--How likely are patients who have undergone radical prostatectomy to present with rising PSA levels and subsequent metastatic progression? Researchers at Memorial Sloan-Kettering Cancer Center employ a computerized tool called a nomogram to find the answer.
Prostate cancer management shows major shifts in PSA era
May 1st 2005Orlando, FL--The management of localized prostate cancer has undergone a significant, dramatic shift in recent years. Both pure and robot-assisted laparoscopic prostatectomy appears to be a viable treatment option that is popular with patients; watchful waiting has declined, despite the stage migration seen in the PSA era; and hormonal therapy has become more widely used in low-risk patients, a source of controversy.
Medicare changes for 2006: More bad news for MDs, patients
May 1st 2005Washington--Both physicians and Medicare beneficiaries are in for a jolt next year, according to government officials who indicated in late March that Medicare will slash physician payments by 4.3% in 2006 and slap beneficiaries with an $11 per month premium increase.
PDE-5 inhibitors effective in men on antidepressants
May 1st 2005Montreal--Phosphodiesterase type-5 inhibitors appear to be effective in treating erectile dysfunction in men who are also receiving pharmacologic treatment for depression. A retrospective study presented here at the Canadian Psychiatric Association annual meeting that looked specifically at tadalafil (Cialis) demonstrated that the drug was effective in improving erections and achieving intercourse in this population.
Adding antiandrogen to castration improves survival
May 1st 2005Orlando, FL--What are the benefits of combining castration with a nonsteroidal antiandrogen in the treatment of advanced prostate cancer? Laurence Klotz, MD, of the University of Toronto, has found a high probability that bicalutamide (Casodex), 50 mg/day, plus castration provides a survival advantage over castration alone.
Estrogen receptor modulator prevents PCa in some men
May 1st 2005Orlando, FL--Testosterone's effect on the development and progression of BPH and prostate cancer is well known, but a group of University of Tennessee researchers has been focusing on testosterone's less frequently studied "partner in crime"—estrogen.
Phase II trials of prostate Ca vaccine promising
May 1st 2005Orlando, FL--A genetically modified vaccine has demonstrated immunogenicity and clinical activity in hormone-refractory prostate cancer patients with metastatic disease, researchers reported in a poster presentation at the 2005 Multidisciplinary Prostate Cancer Symposium.
Latency time about 5 minutes shorter in PE sufferers
April 21st 2005The average intravaginal ejaculatory latency time of premature ejaculation sufferers is 1.8 minutes, versus 7.3 minutes in men without PE, according to a large epidemiologic study published in The Journal of Sexual Medicine (2005; 2:358).
Latency time about 5 minutes shorter in PE sufferers
April 21st 2005The average intravaginal ejaculatory latency time of premature ejaculation sufferers is 1.8 minutes, versus 7.3 minutes in men without PE, according to a large epidemiologic study published in The Journal of Sexual Medicine (2005; 2:358).
Investigational OAB agent shows significant improvements in phase III trial
April 21st 2005An agent under investigation for treatment of overactive bladder demonstrated statistically significant improvements over placebo in phase III trials, according to Schwarz Pharma, which is developing the drug, fesoterodine.
Indian urologists to hold first educational session concurrent with AUA meeting
April 8th 2005The Indian American Urological Association (IAUA) said it will hold its educational program under the auspices of AUA for the first time next month. The program is scheduled for May 21 at the Marriott Riverwalk, San Antonio, TX.
Some men may experience vision loss after taking PDE-5 inhibitor
April 8th 2005Within 36 hours after ingesting sildenafil citrate (Viagra) for erectile dysfunction, some men have nonarteritic anterior ischemic optic neuropathy (NAION), described as "stroke of the eye," according to a report of seven cases published in the Journal of Neuro-ophthalmology (2005; 25:9-13).
Study will test testosterone gel in hypogonadal men with diabetes
April 8th 2005Testosterone gel (AndroGel) 1% will be evaluated for its efficacy and safety as an adjunct to oral hypoglycemic therapy in men with type 2 diabetes and hypogonadism, according to its manufacturer, Solvay Pharmaceuticals, Inc.
Two-drug combination shows positive results in men with ED
April 8th 2005A clinical study evaluating the effect of co-administration of an investigational intranasal agent PT-141 and sildenafil citrate (Viagra) shows positive results in patients with erectile dysfunction, according to researchers from Palatin Technologies Inc. and King Pharmaceuticals Inc.
Injectable LHRH agonist now available nationwide
April 8th 2005The FDA has approved triptorelin pamoate for injectable suspension (Trelstar Depot, 3.75 mg, and Trelstar LA 11.25 mg). The sustained-release, 1- and 3-month intramuscular injectable formulations are now available nationwide for the palliative treatment of advanced prostate cancer when orchiectomy or estrogen administration are either not indicated or are unacceptable to the patient.
Hormonal therapy post-radiation increases survival in PCa patients
April 8th 2005Androgen suppression immediately after radiotherapy in high-risk prostate cancer patients reduces the disease progression and significantly improves survival, according to long-term data published in the International Journal of Radiation Oncology*Biology*Physics (2005; 61:1285-90).